Imago BioSciences, Inc. (Imago) (NASDAQ: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), has announced the closing of US$134.4 million in gross…

The post Latham & Watkins Advises Imago BioSciences on its Upsized Initial Public Offering appeared first on Legal Desire.


Leave a Reply

Your email address will not be published. Required fields are marked *